Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, 10mM in DMSO Moligand™ for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 4 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
T0070907 is a potent and selectivePPARγinhibitor withIC50of 1 nM in a cell-free assay, with a >800-fold selectivity over PPARα and PPARδ. T0070907 significantly decreases the levels ofDNA-PKcsandRAD51proteins in ME-180 and SiHa cells.
In vitro
T0070907 is a potent and selective PPARγ antagonist. With an apparent binding affinity (concentration at 50% inhibition of [3H] rosiglitazone binding or IC50) of 1 nM, T0070907 covalently modifies PPARγ on cysteine 313 in helix 3 of human PPARγ2. T0070907 blocks PPARγ function in both cell-based reporter gene and adipocyte differentiation assays. Consistent with its role as an antagonist of PPARγ, T0070907 blocks agonist-induced recruitment of coactivator-derived peptides to PPARγ in a homogeneous time-resolved fluorescence-based assay and promotes recruitment of the transcriptional corepressor NCoR to PPARγ in both glutathione S-transferase pull-down assays and a PPARγ/retinoid X receptor (RXR) α-dependent gel shift assay. Studies with mutant receptors suggest that T0070907 modulates the interaction of PPARγ with these cofactor proteins by affecting the conformation of helix 12 of the PPARγ ligand-binding domain. Interestingly, whereas the T0070907-induced NCoR recruitment to PPARγ/RXRα heterodimer can be almost completely reversed by the simultaneous treatment with RXRα agonist LGD1069, T0070907 treatment has only modest effects on LGD1069-induced coactivator recruitment to the PPARγ/RXRα heterodimer. T0070907 treatment inhibits proliferation, invasion and migration but does not significantly affect apoptosis. Molecular inhibition using a dominant negative (Δ462) receptor yields similar results. T007 also mediates a dose-dependent decrease in phosphorylation of PPARγ, and its ability to bind to DNA, and may directly affect mitogen-activated protein kinase signaling.
In vivo
Lipopolysaccharide preconditioning significantly attenuates the development of renal dysfunction, hepatocellular injury, and circulatory failure as well as the increase in the plasma levels of interleukin-1 [beta] caused by severe endotoxemia. T0070907 can attenuate all of these beneficial effects afforded by preconditioning with lipopolysaccharide
Cell Data
cell lines:LNCaP and LAPC4
Concentrations:20 μM and higher concentrations
Incubation Time:48 h
Powder Purity:≥99%
| Isomeri SMILES | C1=CC(=C(C=C1[N+](=O)[O-])C(=O)NC2=CC=NC=C2)Cl |
|---|---|
| WGK Germania | 3 |
| PubChem CID | 2777391 |
| Peso molecolare | 277.66 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Data | Oggetto |
|---|---|---|---|
| Certificate of Analysis | Jul 02, 2026 | T408157 |
| Solubilità | Solubility (25°C) In vitro |
|---|
| 1. Jinmiao Tian, Lichao Zhang, Xiaoqin La, Xiaxia Fan, Aiping Li, Changxin Wu, Yuxuan An, Shuning Yan, Xiushan Dong, Haitao Wu, Zhuoyu Li. (2023) Tumor-secreted GRP78 induces M2 polarization of macrophages by promoting lipid catabolism. CELLULAR SIGNALLING, [PMID:37207940] [10.1016/j.cellsig.2023.110719] |
| 2. Meng-Ke Song, Meng-Qi Wang, Yu-Qing Ruan, Can Cui, Wen-Gang Chen, Opeyemi Joshua Olatunji, Yan Li, Jian Zuo. (2025) Qing-Luo-Yin Eases T Cells-Mediated Angiogenesis in Adjuvant-Induced Arthritis Rats by Activating PPARγ. Journal of Inflammation Research, [PMID:40093952] [10.2147/JIR.S508316] |
| 3. Qing-qing Fang, Yang-jun Gu, Yong Wang, Zheng-cai Wang, Xiao-ying Lin, Kai Guo, Ze-ming Zhuang, Xin-cao Zhong, Li-yun Zhang, Jian Chen, Wei-qiang Tan. (2025) The therapeutic potential of Rosiglitazone in modulating scar formation through PPAR-γ pathway. EUROPEAN JOURNAL OF PHARMACOLOGY, [PMID:40054722] [10.1016/j.ejphar.2025.177445] |
| 4. Yan Jin, Fang Lu, Xi Miaocui, Liu Ziqi, Zhang Shihan, Zhang Yuning, Zhang Yuwei, Xue Ting, Li Jiahang, Huang Yue, Chang Runfeng, Qian Qiuhui, Wang Zejun, Teng Miaomiao, Wang Huili. (2026) Ethylhexyl Diphenyl Phosphate Mediates Oxidative Stress and Energy Metabolism Abnormalities by Affecting Glycolipid Metabolism in Zebrafish during Early Development: Key Regulatory Role of the Peroxisome Proliferator-Activated Receptor Signaling Pathway. ENVIRONMENTAL SCIENCE & TECHNOLOGY, 60 (30): (20740-20756). [PMID:42482340] [10.1021/acs.est.5c06517] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Moligand™ grade guide →